Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Sponsor: Allergan
Listed as NCT02959970, this PHASE4 trial focuses on Acne Vulgaris and remains completed. Sponsored by Allergan, it has been updated 13 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 8 earlier versions
-
Mar 2020 — Apr 2020 [monthly]
Completed PHASE4
-
Jan 2019 — Mar 2020 [monthly]
Completed PHASE4
-
Nov 2018 — Jan 2019 [monthly]
Completed PHASE4
-
Jul 2018 — Nov 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
- Almirall, S.A.
For direct contact, visit the study record on ClinicalTrials.gov .